The Business Times
The Business Times
Subscribe
Share on FacebookShare on TwitterView more
The Business Times
Create a free account with Business Times for seamless access across SPH Media products.
REGISTER
LOGIN

Companies & Markets

Gilead Sciences reports almost US$900m in Q3 remdesivir sales

Published Wed, Oct 28, 2020 · 11:16 PM
Share this article.

[NEW YORK] Remdesivir, a therapeutic to treat Covid-19, boosted third-quarter sales for pharma company Gilead Sciences by nearly US$900 million, according to results released Wednesday by the drugmaker.

The medication, sold under the brand name Veklury, which was originally developed to treat Ebola, has been shown to shorten the recovery time for patients hospitalized with the coronavirus. Gilead reported a 17 per cent jump in third-quarter revenues to US$6.6 billion.

AFP

BT is now on Telegram!

For daily updates on weekdays and specially selected content for the weekend. Subscribe to  t.me/BizTimes

Consumer & Healthcare

SUPPORT SOUTH-EAST ASIA'S LEADING FINANCIAL DAILY

Get the latest coverage and full access to all BT premium content.

SUBSCRIBE NOW

Browse corporate subscription here